Sevuparin sodium is under clinical development by Modus Therapeutics and currently in Phase I for Endotoxemia. According to GlobalData, Phase I drugs for Endotoxemia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sevuparin sodium LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sevuparin sodium overview

Sevuparin sodium (DF-02) is under development for the treatment of malaria, sepsis, endotoxemia, septic shock and chronic kidney disease (CKD) with anemia. It is administered as an intravenous infusion and subcutaneous injection. The drug candidate is a polysaccharide drug derived from heparin, a low anticoagulant heparin (LAH) derivative. It was also under development for the treatment of malaria and acute vaso-occlusive crisis (VOC) associated with sickle cell disease (SCD).

Modus Therapeutics overview

Modus Therapeutics, a subsidiary of Modus Therapeutics Holding AB, is a biotechnology company focused on the development of new drugs for the treatment of sickle cell disease (SCD). The company’s lead product candidate sevuparin is an innovative, proprietary polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects that restores blood flow and prevents further microvascular obstruction in SCD patients. It also develops sevuparin for the management of acute vaso-occlusive crises (VOCs) and the treatment of severe malaria. The company markets its drugs in Sweden and abroad. Modus Therapeutics is headquartered in Stockholm, Sweden.

For a complete picture of Sevuparin sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.